Marinomed Biotech AG (93Z) Stock Statistics & Valuation Metrics
Total Valuation
Marinomed Biotech AG has a market cap or net worth of EUR 9.20M. The enterprise value is EUR 45.78M.
- Market Cap
- EUR 9.20M
- Enterprise Value
- EUR 45.78M
Share Statistics
Marinomed Biotech AG has 2,299,925 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,299,925
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Marinomed Biotech AG’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -43.07%.
- Return on Equity (ROE)
- 0.67
- Return on Assets (ROA)
- -0.47
- Return on Invested Capital (ROIC)
- -43.07%
- Return on Capital Employed (ROCE)
- -1.03
- Revenue Per Employee
- 286.98K
- Profits Per Employee
- -212.34K
- Employee Count
- 32
- Asset Turnover
- 0.63
- Inventory Turnover
- 7.94
Valuation Ratios
The current PE Ratio of Marinomed Biotech AG is -13.21. Marinomed Biotech AG’s PEG ratio is -1.88.
- PE Ratio
- -13.21
- PS Ratio
- 7.50
- PB Ratio
- -20.34
- Price to FCF
- -15.57
- Price to Operating Cash Flow
- -16.25
- PEG Ratio
- -1.88
Income Statement
In the last 12 months, Marinomed Biotech AG had revenue of 9.18M and earned -6.79M in profits. Earnings per share was -4.48.
- Revenue
- 9.18M
- Gross Profit
- 1.14M
- Operating Income
- -5.13M
- Pretax Income
- -6.79M
- Net Income
- -6.79M
- EBITDA
- -3.62M
- Earnings Per Share (EPS)
- -4.48
Cash Flow
In the last 12 months, operating cash flow was -4.14M and capital expenditures 0, giving a free cash flow of -4.14M billion.
- Operating Cash Flow
- -4.14M
- Free Cash Flow
- -4.14M
- Free Cash Flow per Share
- -3.62
Dividends & Yields
Marinomed Biotech AG pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.42%
- Earnings Yield
- -7.57%
Stock Price Statistics
- Beta
- 0.36
- 52-Week Price Change
- -81.59%
- 50-Day Moving Average
- 3.97
- 200-Day Moving Average
- 9.43
- Relative Strength Index (RSI)
- 38.72
- Average Volume (3m)
- 142
Important Dates
Marinomed Biotech AG upcoming earnings date is Apr 21, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 16, 2026
- Next Earnings Date
- Apr 21, 2027
- Ex-Dividend Date
- ―
Financial Position
Marinomed Biotech AG as a current ratio of 0.74, with Debt / Equity ratio of -215.04%
- Current Ratio
- 0.74
- Quick Ratio
- 0.63
- Debt to Market Cap
- 0.49
- Net Debt to EBITDA
- -5.30
- Interest Coverage Ratio
- -3.71
Taxes
In the past 12 months, Marinomed Biotech AG has paid 4,000 in taxes.
- Income Tax
- 4,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Marinomed Biotech AG EV to EBITDA ratio is -30.81, with an EV/FCF ratio of -18.23.
- EV to Sales
- 8.78
- EV to EBITDA
- -30.81
- EV to Free Cash Flow
- -18.23
- EV to Operating Cash Flow
- -19.03
Balance Sheet
Marinomed Biotech AG has EUR 911.50K in cash and marketable securities with EUR 29.09M in debt, giving a net cash position of -EUR 28.18M billion.
- Cash & Marketable Securities
- EUR 911.50K
- Total Debt
- EUR 29.09M
- Net Cash
- -EUR 28.18M
- Net Cash Per Share
- -EUR 12.25
- Tangible Book Value Per Share
- -EUR 13.34
Margins
Gross margin is 18.98%, with operating margin of -43.58%, and net profit margin of -56.74%.
- Gross Margin
- 18.98%
- Operating Margin
- -43.58%
- Pretax Margin
- -56.68%
- Net Profit Margin
- -56.74%
- EBITDA Margin
- -28.49%
- EBIT Margin
- -34.43%
